‘SUB­STAN­DARD’ COMB­I­FLAM FAILS QUALITY TEST, RE­CALLED

Hindustan Times ST (Mumbai) - HT Navi Mumbai Live - - FRONT PAGE - HT Cor­re­spon­dent letters@hin­dus­tan­times.com

NEW DELHI: French drug maker Sanofi is re­call­ing batches of its pop­u­lar painkiller Comb­i­flam in In­dia af­ter the con­cerns flagged by coun­try’s apex drug reg­u­la­tion body, Cen­tral Drugs Stan­dard Con­trol Or­gan­i­sa­tion (CDSCO).

CDSCO has found that the lots were sub­stan­dard, and said in no­tices posted on its web­site in Fe­bru­ary and April that it had found some batches of Comb­i­flam to be “not of stan­dard quality” as they failed dis­in­te­gra­tion tests.

Comb­i­flam is a com­bi­na­tion of parac­eta­mol and ibupro­fen, and is one of Sanofi’s five big­gest brands in In­dia, ac­cord­ing to the com­pany’s lat­est avail­able an­nual re­port dated March 2015. “Some batches of Comb­i­flam tablets were found to have a de­layed dis­in­te­gra­tion time. There is a phar­ma­ceu­ti­cal pa­ram­e­ter that re­quires the break­down of a tablet in the hu­man body to be as­sessed,” said Sanofi In­dia spokesperson.

CON­TIN­UED ON P11

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.